PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29577719-0	2018	Anisamide-Anchored Lyotropic Nano-Liquid Crystalline Particles with AIE Effect: A Smart Optical Beacon for Tumor Imaging and Therapy.	anisamide	0-9	ubiquitin like 5	Homo sapiens	96-102
30779980-6	2019	In vitro, anisamide-targeted AuNPs selectively bound to human prostate cancer PC-3 cells, inducing efficient endosomal escape of siRNA, and effective downregulation of the RelA gene.	anisamide	10-19	RELA proto-oncogene, NF-kB subunit	Homo sapiens	172-176
30779980-7	2019	In vivo, prolonged systemic exposure of siRNA was achieved by anisamide-targeted AuNPs resulting in significant tumour growth suppression in a PC3 xenograft mouse model without an increase in toxicity.	anisamide	62-71	chromobox 8	Mus musculus	143-146
25938556-2	2015	Here, novel anisamide-decorated pH-sensitive degradable chimaeric polymersomes (Anis-CPs) were designed, prepared, and investigated for efficient and targeted delivery of apoptotic protein, granzyme B (GrB), to lung cancer cells.	anisamide	12-21	granzyme B	Homo sapiens	202-205
22686936-2	2012	To explore the potential of small interfering RNA (siRNA) therapy for NSCLC, we have developed anisamide-targeted LCP to efficiently deliver siRNA into the cytoplasm of sigma receptor-expressing NSCLC cells.	anisamide	95-104	kelch domain containing 2	Homo sapiens	114-117
25596376-2	2015	We used anisamide-targeted lipid-calcium-phosphate (LCP) nanoparticles to efficiently deliver HIF1alpha siRNA to the cytoplasm of sigma receptor-expressing SCC4 and SAS cells that were also subjected to photodynamic therapy (PDT).	anisamide	8-17	hypoxia inducible factor 1 subunit alpha	Homo sapiens	94-103
25596376-2	2015	We used anisamide-targeted lipid-calcium-phosphate (LCP) nanoparticles to efficiently deliver HIF1alpha siRNA to the cytoplasm of sigma receptor-expressing SCC4 and SAS cells that were also subjected to photodynamic therapy (PDT).	anisamide	8-17	MAU2 sister chromatid cohesion factor	Homo sapiens	156-160
22828585-3	2012	Following intravenous administration of the anisamide-targeted formulation in a mouse prostate tumour model significant tumour inactivation with corresponding reductions in the level of vascular endothelial growth factor (VEGF) mRNA were achieved, without demonstrating enhanced toxicity.	anisamide	44-53	vascular endothelial growth factor A	Mus musculus	186-220
22828585-3	2012	Following intravenous administration of the anisamide-targeted formulation in a mouse prostate tumour model significant tumour inactivation with corresponding reductions in the level of vascular endothelial growth factor (VEGF) mRNA were achieved, without demonstrating enhanced toxicity.	anisamide	44-53	vascular endothelial growth factor A	Mus musculus	222-226